Advertisement

Familiäres Nierenkarzinom

  • Hartmut P. H. Neumann
  • Oliver Gimm
  • Wilhelm Krek
  • Bin Tean Teh
  • Berton Zbar
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Familiäre Nierenkarzinome kommen selten vor. Als Rarität erschienen sie zunächst ohne weitere Bedeutung. Im Verlauf der 80er und der 90er Jahre hat die wissenschaftliche Erforschung der hereditären Nierentumoren jedoch Meilensteine gesetzt: Es gelangen die Kartierung und in jüngster Zeit die Identifizierung von pathogenetisch relevanten Genen. Dies hat zu einem völlig neuen Verständnis der Entstehung aller, d.h. auch der sporadischen Nierenkarzinome geführt. Nierenkarzinome lassen sich somit nicht nur morphologisch, sondern in zunehmendem Maß auch molekularbiologisch charakterisieren. Inwieweit Therapieoptionen und Prognose auch unter diesen neuen Aspekten überdacht werden müssen, lässt sich allerdings bislang nur für hereditäre Nierenkarzinome sagen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Al-Saleem T, Wessner LL, Schelthauer BW et al. (1998) Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83:2208–2216PubMedCrossRefGoogle Scholar
  2. Amin MB, Crotty TB, Tickoo SK, Farrow GM (1997) Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol 21:1–12PubMedCrossRefGoogle Scholar
  3. Anonymus (1996) Genetic testing for cancer susceptibility. J Clin Oncol 14:1730–1736Google Scholar
  4. Aoyama T, Fujikawa K, Yoshimura K, Sasaki M, Itoh T (1996) Bilateral renal cell carcinoma in a patient with tuberous sclerosis. Int J Urol 3:150–151PubMedCrossRefGoogle Scholar
  5. Beckmann H, Su LK, Kadesch T (1990) TFE3: a helixloophelix protein that activates transcription through the immunoglobulin enhancer E3 motif. Gene Dev 4:167–179PubMedCrossRefGoogle Scholar
  6. Bender BU, Weiterauer U, Schollmeyer P, Neumann HPH (1997) An incidental finding — bilateral multifocal renal oncocytoma. Nephrol Dial Transplant 12:1034–1036PubMedCrossRefGoogle Scholar
  7. Bernues M, Casadevall C, Miro R et al. (1995) Cytogenetic characterization of a familial papillary renal cell carcinoma. Cytogenet Cell Genet 84:123–127CrossRefGoogle Scholar
  8. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP (1996) Tuberous sclerosis associated renal carcinoma. Clinical, pathological and genetic features. Am J Pathol 149:1201–1208PubMedGoogle Scholar
  9. Bodmer, D, Eleveld MJ, Ligtenberg MJL. et al. (1998) An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3) (q35;q21) chromosome translocation. Am J Hum Cenet 62:1475–1483CrossRefGoogle Scholar
  10. Brauch H, Weirich G, Hornauer MA, Störkel S, Wohl T, Bruening T (1999) Mutation spectrum in trie h loro ethylene exposed patients with renal cell carcinoma. J Natl Cancer Inst 91:854–861PubMedCrossRefGoogle Scholar
  11. Brüning T, Weirich G, Hornauer MA, Höfler H, Brauch H (1997) Renal cell carcinomas in trichloroefhylene (TRI) exposed persons are associated with somatic mutations in the von Hippel-Lindau (VHL) tumor suppressor gene. Arch Toxicol 71:332–335PubMedCrossRefGoogle Scholar
  12. Bugert P, Gaul C, Weber K et al. (1997) Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Invest 76:203–208PubMedGoogle Scholar
  13. Bundesärztekammer (1998) Richtlinien zur Diagnostik der genetischen Disposition für Krebserkrankungen. Dtsch Arztebl 95:A1396–1403Google Scholar
  14. Carbonara C, Longa L, Grosso E et al. (1994) 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppress or-like activity also for the TSC1 gene. Hum Mol Genet 3:1829–1832PubMedCrossRefGoogle Scholar
  15. Chauveau D, Duvic C, Chretien Y et al. (1996) Renal involvement of von Hippel-Lindau disease. Kidney Int 50:944–951PubMedCrossRefGoogle Scholar
  16. Chen F, Kishida T. Duh FM et al. (1995a) Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55:4804–4807PubMedGoogle Scholar
  17. Chen F, Kishida T, Yao M et al. (1995b) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75PubMedCrossRefGoogle Scholar
  18. Choyke PL, Glenn GM, Wagner JP et al. (1997) Epididymal cystadenomas in von Hippel-Lindau disease. Urology 49:926–931PubMedCrossRefGoogle Scholar
  19. Chudek J, Herbers J, Wilhelm M et al. (1998) The genetics of renal tumors in end-stage renal failure differs from those occurring in the general populalion. J Am Soc Nephrol 9:1045–1051PubMedGoogle Scholar
  20. Clark J, Lu YJ, Sidhar SK et al. (1997) Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15:2233–2239PubMedCrossRefGoogle Scholar
  21. Cohen AJ, Li FP, Berg S et al. (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301:592–595PubMedCrossRefGoogle Scholar
  22. Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G (1997) Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol 181:136–139PubMedCrossRefGoogle Scholar
  23. Cooper CS (1992) The met oncogene: from detection by transfeciion to transmembrane receplor for hepatocyte growth factor. Oncogene 7:3–7PubMedGoogle Scholar
  24. Cooper CS, Park M, Blair DG et al. (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29–33PubMedCrossRefGoogle Scholar
  25. Corless CL, Aburatani H, Fletcher JA, Housman DE, Amin MB, Weinberg DS (1996) Papillary renal carcinoma. Quantitation of chromosomes 7 and 17 by FISH analysis and of chromosome 3p for LOH and DNA ploidy. Diagn Mod Pathol 5:53–64CrossRefGoogle Scholar
  26. Crossey PA, Richards FM, Foster K et al. (1994) Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 3:1303–1308PubMedCrossRefGoogle Scholar
  27. Crotty TB, Lawrence KM. Moertel CA et al. (1992) Cytogenetic analysis of six renal oncocytomas and a chromophobe cell renal carcinoma. Evidence that-Y,-1 may be a characteristic anomaly in renal oncoevtomas. Cancer Genet Cytogenet 61:61–66PubMedCrossRefGoogle Scholar
  28. Crotty TB, Farros GM, Lieber MM (1995) Chromophobe cell renal carcinoma: clini cop athologic features of 50 cases. J Urol 154:964–967PubMedCrossRefGoogle Scholar
  29. Davis CJ, Mostofi FK, Sesterhenn IA (1995) Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 19:1–11PubMedCrossRefGoogle Scholar
  30. Decker H, Gemili R, Neumann HPH, Walter T, Sandberg (1988) A loss of heterocygosity on 3p in an Von Hippel-Lindau renal cell carcinoma. Cancer Genet Cytogenet 39:289–293CrossRefGoogle Scholar
  31. Delahunt B, Eble J (1997) Papillary renal cell carcinoma: a histological and immunohistochemical study of 105 tumors. Mod Pathol 10:537–544PubMedGoogle Scholar
  32. Duan DR, Pause A, Burgess WH et al. (1995) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402–1406PubMedCrossRefGoogle Scholar
  33. Duh FM, Scherer SW, Tsui LC, Lerman M, Zbar B, Schmidt L (1997) Gene structure of the humen MET protooncogene. Oncogene 15:1583–1586PubMedCrossRefGoogle Scholar
  34. Eng C (1996) The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung’s disease. N Engl J Med 335:943–951PubMedCrossRefGoogle Scholar
  35. Eng C, Smith DP, Mulligan LM et al. (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237–241PubMedCrossRefGoogle Scholar
  36. Ermis A, Henn W, Remberger K, Hopf C, Hopt T, Zang KD (1995) Proliferation enhancement by spontaneous multiplication of chromosome 7 in rheumatic synovial cells in vitro. Hum Genet 96:651–654PubMedCrossRefGoogle Scholar
  37. European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and chracterization of the tuberous sclerosis gene on chromosome 16. Cell 75:1305–1315CrossRefGoogle Scholar
  38. Fairchild TN, Dail D, Brannen FE (1983) Renal oncocytoma — bilateral, multifocal. Urology 22:355–359PubMedCrossRefGoogle Scholar
  39. Foster K, Prowse A, Berg A van den et al. (1994) Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3:2169–2173PubMedCrossRefGoogle Scholar
  40. Garrett KP, Aso T, Bradsher JN et al. (1995) Positive regulation of general transcription factor SHI by tailed ubiquitin homolog. Proc Natl Acad Sci USA 92:7172–7176PubMedCrossRefGoogle Scholar
  41. Gemmili RM, West JD, Boldog F et al. (1998) The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci USA 95:9572–9577CrossRefGoogle Scholar
  42. Gläsker S, Bender BU, Apel TW et al. (1999) The impact of molecular genetic analysis of the VHL-gene in patients with haemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry 67:758–762PubMedCrossRefGoogle Scholar
  43. Glavac D, Neumann HPH, Wittke C et al. (1996) Mutations in the VHL tumor suppressor gene and associated lesions in families with Von Hippel-Lindau disease from central Europe. Hum Genet 98:271–280PubMedCrossRefGoogle Scholar
  44. Glenn GM, Daniel LN, Choyke P et al. (1991) Von Hippel-Lindau (VHL) disease: distinct phenolypes suggest more than one mutant allele at the VHL locus. Hum Genet 87:207–210PubMedCrossRefGoogle Scholar
  45. Glenn GM, Stolle C, Sgambati M et al. (1999) New mutations versus silent carrier-parent as source of first generation diagnoses in a hereditary neoplastic disorder: von Hippel-Lindau disease. Proc Am Assoc Cancer Res 40:464Google Scholar
  46. Glukhova L, Goguel AF, Chudoba I et al. (1998) Overrepresentation of 7q31 and 17q in renal cell carcinomas. Genes Chromosomes Cancer 22:171–178PubMedCrossRefGoogle Scholar
  47. Gnarra JR, Tory K, Weng Y et al. (1994) Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 7:85–90PubMedCrossRefGoogle Scholar
  48. Green AJ, Johnson PH, Yates JRW (1994a) The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet 3:1833–1834PubMedCrossRefGoogle Scholar
  49. Green AJ, Smith M, Yates JRW (1994b) Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 6:193–196PubMedCrossRefGoogle Scholar
  50. Gronwald J, Baur AS, Holtgreve-Grez H et al. (1999) Chromosomal abnormalities in renal cell neoplasms associated with acquired renalcystic disease. A series studied by comparative genomic hybridization and fluorescence in situ hybridization. J Pathol 187:308–312PubMedCrossRefGoogle Scholar
  51. Gunawan B, Bergmann F, Braun S et al. (1999) Polyploidization and loss of chromosomes 1, 2, 6, 10, 13, and 17 in three cases of chromophobe renal cell carcinomas. Cancer Genet Cytogenet 57:5009–5012Google Scholar
  52. Hara M, Yostlida K, Tomita M, Akimoto M, Kawai H, Fukuda Y (1982) A case of bilateral renal oncocytoma. J Urol 128:576–578PubMedGoogle Scholar
  53. Henske EP, Neumann HPH, Scheithauer BW et al. (1995) Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 13:295–298PubMedCrossRefGoogle Scholar
  54. Herman JG, Latif F, Weng Y et al. (1994) Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700–9704PubMedCrossRefGoogle Scholar
  55. Hofstra RMW, Landsvater RM, Ceccerini I et al. (1994) A mutation in the RET pro to-oncogen e associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375–376PubMedCrossRefGoogle Scholar
  56. Hosoe S, Brauch H, Latif F et al. (1990) Localization of the von Hippel-Lindau gene to a small region of chromosome 3. Genomics 8:634–640PubMedCrossRefGoogle Scholar
  57. Hughson MD, Schmidt L, Zbar B et al. (1996) Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study. J Am Soc Nephrol 7:2461–2468PubMedGoogle Scholar
  58. Hughson MD, Bigler S, Dickmann K, Kovacs G (1999) Renal cell carcinoma of end-stage renal disease: an analysis of chromosome 3, 7 and 17 abnormalities by microsatellite amplification. Mod Pathol 12:301–309PubMedGoogle Scholar
  59. Uiopoulos O, Kibel A, Gray S, Kaefin WG (1995) Tumor suppression bv the human von Hippel-Lindau gene product. Nat Med L822–826Google Scholar
  60. Uiopoulos O, Olili M, Kaelin WG (1998) pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 95: 11.661–11.666Google Scholar
  61. Ishikawa I, Kovacs G (1993) High incidence of papillary renal cell tumors in patients on chronic hemodialysis. Hislopathology 22:135–139CrossRefGoogle Scholar
  62. Israeli RS, Wise GJ, Bansal S, Gerard PS, Castela A (1995) Bilateral renal oncocytomatosis in a patient with renal failure. Urology 46:873–875PubMedCrossRefGoogle Scholar
  63. Iwai K, Yamanaka K, Kamura T et al. (1999) Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96:12.436–12.441CrossRefGoogle Scholar
  64. Janetschek G, Finkenstedt G, Casser R et al. (1998) Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol 160:330–334PubMedCrossRefGoogle Scholar
  65. Jeffers M, Schmidt L, Nakaigawa N et al. (1997) Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 94:11.445–11.450CrossRefGoogle Scholar
  66. Jiang F, Richter J, Schraml P et al. (1998) Chromosomal imbalances in papillary renal cell carcinoma: genetic differences betweeen histological subtypes. Am J Pathol. 93:9154–9159Google Scholar
  67. Kadewsky KT, Fulgham PF (1993) Bilateral multifocal renal oncocytoma: case report and review of the literature. J Urol 150:1227–1228Google Scholar
  68. Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M (1998) Functions of the von Hippel-Lindau tumor suppressor protein. J Intern Med 243:535–539PubMedCrossRefGoogle Scholar
  69. Kamura T, Koepp DM, Conrad MN et al. (1999) Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657–661PubMedCrossRefGoogle Scholar
  70. Kardas I, Denis A, Babinska M et al. (1998) Translocation (X;1) (p11.2;q21) in a papillary renal cell carcinoma in a 14-year-old-girl. Cancer Genet Cytogenet 101:1959–1961Google Scholar
  71. Katagiri F, Seipel K, Chua NH (1992) Identification of a novel dimer stabilization region in a plant bZIP transcription activator. Mol Cell Biol 12:4809–4816PubMedGoogle Scholar
  72. Kattar MM, Grignon DJ, Wallis T et al. (1997) Clinicopathologic and interphase cytogenetic analysis of papillary (chromophilic)renal cell carcinoma. Mod Pathol 10:1143–1150PubMedGoogle Scholar
  73. Keeler LL, Klauber GT (1992) Von Hippel-Lindau disease and renal cell carcinoma in a 16-year-old boy. J Urol 147:1588–1591PubMedGoogle Scholar
  74. Kempermann G, Neumann HPH, Scheremet R et al. (1996) Deafness due to bilateral endolymphatic sac tumor in a case of Von Hippel-Lindau syndrome: J Neurol Neurosurg Psychiatry 61:318–320PubMedCrossRefGoogle Scholar
  75. Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G (1996) Mutation of the VHL-gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 179:157–161PubMedCrossRefGoogle Scholar
  76. Kessler PM, Vasavada SP, Rackley RR et al. (1995) Expression of the von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1:457–466PubMedGoogle Scholar
  77. Kibel A, Uiopoulos O, DeCarpio JA, Kaelin WG (1995) Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269:1444–1446PubMedCrossRefGoogle Scholar
  78. King CR, Schimke RN, Arthur T, Davoren B, Collins D (1987) Proximal 3p deletion in renal cell carcinoma cells from a patient with von Hippel-Lindau disease. Cancer Genet Cytogenet 27:345–348PubMedCrossRefGoogle Scholar
  79. Kinzler KW, Vogelstein B (1996) Lesson from hereditary colorectal cancer. Cell 87:159–170PubMedCrossRefGoogle Scholar
  80. Kitayama H, Kanakura Y, Furitsu T et al. (1995) Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor independent growth and tumorigenicity of factor-de pendent hematnpoetic cell lines. Blood 85:790–798PubMedGoogle Scholar
  81. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedCrossRefGoogle Scholar
  82. Koepp DM, Harper JW, Elledge SJ (1999) How cyclin became a cyclin: regulated proteolysis in cell cycle Cell 97:431–434PubMedCrossRefGoogle Scholar
  83. Kondo K, Kobayashi K, Kishida T et al. (1997) FHIT gene is not mutated in sporadic renal cell carcinoma. Proc Am Assoc Cancer Res 38:275Google Scholar
  84. Kovacs G (1989) Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases. Am J Pathol 134:27–34PubMedGoogle Scholar
  85. Kovacs G, Hoene E (1988) Loss of der(3) in renal carcinoma cell of a patients with constitutional t(3;12). Hum Genet 78:148–150PubMedCrossRefGoogle Scholar
  86. Kovacs G, Kovacs A (1993) Parenchymal abnormalities associated with papillary renal cell tumors: a morphologic study. J Urol Pathol 1:301–312Google Scholar
  87. Kovacs G, Kung HF (1991) Nonhomologous chromatid exchange in hereditary and sporadic renal cell carcinomas. Proc Natl Acad Sci USA 88:194–198PubMedCrossRefGoogle Scholar
  88. Kovacs G, Erlandsson R, Boldog F et al. (1988) Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 85:1571–1575PubMedCrossRefGoogle Scholar
  89. Kovacs G, Brusa P, De Riese W (1989a) Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 43:422–427PubMedCrossRefGoogle Scholar
  90. Kovacs G, Welter C, Wilkens L, Blin N, De Riese W (1989b) Renal oncocytoma: a phenotypic and genotypic entity of renal parenchymal tumors. Am J Pathol 134:967–971PubMedGoogle Scholar
  91. Kovacs G, Emanuel A, Neumann HP, Kung HF (1991) Cytogenetics of renal cell carcinoma associated with von Hippel-Lindau disease. Genes Chromosome Cancer 3:256–262CrossRefGoogle Scholar
  92. Kovacs A, Störkel S, Thoenes W, Kovacs G (1992) Mitochrondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas. J Pathol 167:273–277PubMedCrossRefGoogle Scholar
  93. Kovacs G, Akhtar M, Beckwith JB et al. (1997) Heidelberg classification of renal parenchymal tumors. J Pathol 183:131–133PubMedCrossRefGoogle Scholar
  94. Kshirsagar AV, Choyke PL, Linehan WM, Walther MM (1998) Pseudotumors after renal parenchymal sparing surgery. J Urol 159:1148–1151PubMedCrossRefGoogle Scholar
  95. Lamiell JM, Salazar RG, Hsia YE (1989) Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 68:1–29Google Scholar
  96. Latif F, Tory T, Gnarra J et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320PubMedCrossRefGoogle Scholar
  97. Lee S, Neumann M, Stearman R et al. (1999) Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 19:1486–1497PubMedGoogle Scholar
  98. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W (1999) The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Gene Dev 13:1822–1833PubMedCrossRefGoogle Scholar
  99. Lonergan KM, Uiopoulos O, Ohh M et al. (1998) Regulation of hypoxia-in du cible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18:732–741PubMedGoogle Scholar
  100. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z (1996) Allelic deletions of the VHL-gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149:2089–2094PubMedGoogle Scholar
  101. Lynch HT, Ens JA, Lynch JF (1990) The Lynch syndrome II and urological malignancies. J Urol 143:24–28PubMedGoogle Scholar
  102. Lynch HT, Smyrk T, Lynch J (1997) An update of HNPCC (Lynch syndrome). Cancer Genet Cytogenet 93:84–99PubMedCrossRefGoogle Scholar
  103. Maddock IR, Moran A, Maher et al. (1996) A genetic register for von Hippel-Lindau disease. J Med Genet 33:120–127PubMedCrossRefGoogle Scholar
  104. Maher ER (1990) Clinical features and natural history of von Hippel-Lindau disease. QJM 77:1151–1163PubMedCrossRefGoogle Scholar
  105. Maher ER, Kaelin WG (1997) Von Hippel-Lindau disease. Medicine (Baltimore) 76:381–391CrossRefGoogle Scholar
  106. Maher ER, Bentley E, Yates JRW et al. (1991a) Mapping of the von Hippel-Lindau disease locus to a small region of chromosome 3p by linkage analysis. Genomics 10:957–960PubMedCrossRefGoogle Scholar
  107. Mäher ER, Iselius L, Yates JR et al. (1991b) Von Hippel-Lindau disease: a genetic study. J Med Genet 28:443–447PubMedCrossRefGoogle Scholar
  108. Mandlla-Jimenez R, Stanley RJ, Blath RA (1976) Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer 38:2469–2480CrossRefGoogle Scholar
  109. Manski TJ, Heffner DK, Glenn DM et al. (1997) Endolymphatic sac tumors: a source of morbid hearing loss in von Hippel-Lindau disease. J Am Med Assoc 277:1461–1466CrossRefGoogle Scholar
  110. Maxwell PH, Wiesener MS, Chang GW et al. (1999) The tumor suppressor protein VHL targets hypoxia-inducible factorsforoxygen-dependentproteolysis. Nature 399:271–275PubMedCrossRefGoogle Scholar
  111. Mead GO, Thomas LR Jr, Jackson JG (1990) Renal oncocytoma: report of a case with bilateral multifocal oncocytomas. Clin Imaging 14:231–233PubMedCrossRefGoogle Scholar
  112. Melmon KL, Rosen SW (1964) Lindau’s disease: review of the literature and study of a large kindred. Am J Med 36:595–617PubMedCrossRefGoogle Scholar
  113. Meloni AM, Dobbs RM, Pontes JE, Sandberg AA (1993) Translocation (X;1) in papillary renal adenocarcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet 65:1–6PubMedCrossRefGoogle Scholar
  114. Mostofi FK, Davis CJ (1998) Histological typing of kidney tumours, 2nd edn. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  115. Nagata H, Worobec AS, Oh CK et al. (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Nail Acad Sci USA 92:10.560–10.564Google Scholar
  116. Neumann HPH (1987a) Basic criteria for clinical diagnosis and genetic counseling in Von Hippel-Lindau syndrome. J Vase Dis 16:220–226Google Scholar
  117. Neumann HPH (1987 b) Prognosis of Von Hippel-Lindau syndrome. J Vase Dis 16:309–311Google Scholar
  118. Neumann HPH (1998) Von Hippel-Lindau Krankheit. EigenverlagGoogle Scholar
  119. Neumann HPH, Bender BU (1998) Genotype-phenotype correlations in Von Hippel-Lindau disease. J Intern Med 43:541–545Google Scholar
  120. Neumann HPH, Kandt RS (1998) Klinik und Genetik der Tuberösen Sklerose. Dtsch Med Wochenschr 118:1577–1583CrossRefGoogle Scholar
  121. Neumann HPH, Wiestier OD (1991) Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337:1052–1054PubMedCrossRefGoogle Scholar
  122. Neumann HPH, Zbar B (1997) Renal cysts, renal cancer and Von Hippel-Lindau disease. Kidney Int 51:16–26PubMedCrossRefGoogle Scholar
  123. Neumann HPH, Berger DP, Blum U et al. (1993) Pheochromocytomas, multiple endocrine neoplasia lype 2, and Von Hippel-Lindau syndrome. N Engl J Med 329:1351–1358CrossRefGoogle Scholar
  124. Neumann HPH, Bender BU, Berger DP et al. (1998) Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 160:1248–1254PubMedCrossRefGoogle Scholar
  125. Neumann HPH, Bender BU, Reincke M, Eggstein S, Laubenberger J, Kirste G (1999 a) Adrenal sparing surgery for phaeochromocytoma. Br J Surg 84:94–97CrossRefGoogle Scholar
  126. Neumann HPH, Reincke M, Bender BU, Eisner R, Janetschek G (1999b) Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 84:2608–2610PubMedCrossRefGoogle Scholar
  127. Ohh M, Kaelin W (1999) The Von Hippel Lindau tumor suppressor protein. New perspectives. Mol Med Today 5:257–263PubMedCrossRefGoogle Scholar
  128. Ohh M, Yauch RL, Lonergan et al. (1998) The von Hippel-Lindau tumor suppressor protein is required for propper assembly of an extracellular fibronectin matrix. Mol Cells 1:959–968CrossRefGoogle Scholar
  129. Ohta M, Inoue H, Cotticelli MG et al. (1996) The FHIT gene, spanning the chromosome 3p 13.2 fragile site and renal carcinoma-associated t(3;8) breakpoint is abnormal in digestive tract cancers. Cell 84:587–597PubMedCrossRefGoogle Scholar
  130. Olivero M, Rizzo M, Madeddu R et al. (1996) Overexpression and activation of hepatocyte growth factor/scatter factor in human non-s mall-cell lung carcinoms. Br J Cancer 74:1862–1868PubMedCrossRefGoogle Scholar
  131. Palmedo G, Fischer J, Kovacs G (1999) Duplications of DNA sequences between loci D20S478 and D20S206 at 20q11.2 and between loci D20S902 and D20S480 at 20q13.2 mark new tumor genes in papillary renal cell carcinoma. Lab Invest 79:311–316PubMedGoogle Scholar
  132. Park M, Dean M, Cooper CS et al. (1986) Mechanism of met oncogene activation. Cell 45:895–904PubMedCrossRefGoogle Scholar
  133. Patton EE, Willems AR, Tyers M (1998) Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F box hypothesis. Trends Genet 14:263–243CrossRefGoogle Scholar
  134. Pause A, Lee S, Worrell RA et al. (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Nat Acad Sci USA 94:2156–2161PubMedCrossRefGoogle Scholar
  135. Perot C, Bougaran J, Boccon-Gibod L et al. (1999) Two new cases of papillary renal cell carcinoma with t(X;1) (p11;q21) in females. Cancer Genet Cytogenet 110:54–56PubMedCrossRefGoogle Scholar
  136. Piao X, Bernstein A (1996) A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity and differentiation of mast cells. Blood 87:3117–3123PubMedGoogle Scholar
  137. Piao X, Paulson R, Geer P van der, Pawson T, Bernstein A (1996) Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degredation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci USA 93:14.665–14.669CrossRefGoogle Scholar
  138. Ponder BAH, Smith D (1996) The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res 70:179–222PubMedCrossRefGoogle Scholar
  139. Poston CD, Jaffe GS, Lubensky IA et al. (1995) Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153:22–26PubMedCrossRefGoogle Scholar
  140. Prowse, AH, Webster AR, Richards FM et al. (1997) Somatic inactivation of the VHL-gene in von Hippel-Lindau disease tumors. Am J Hum Genet 60:765–771PubMedGoogle Scholar
  141. Richards FM, Schofield PN, Fleming S, Mäher ER (1996) Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 5:639–644PubMedCrossRefGoogle Scholar
  142. Robertson FM, Cendron M, Klauber GT, Harris BH (1996) Renal cell carcinoma in association with tuberous sclerosis in children. J Pediatr Surg 31:729–730PubMedCrossRefGoogle Scholar
  143. Rongioletti F, Hazini R, Gianotti G, Rebora A (1989) Fibrofolliculomas, tricodiscomasand acrochordons (Birt-Hogg-Dube) associated with intestinal polyposis. Clin Exp Dermatol 14:72–74PubMedCrossRefGoogle Scholar
  144. Roth JS, Rabinowitz AD, Benson M, Grossman ME (1993) Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 29:1055–1056PubMedCrossRefGoogle Scholar
  145. Rubin JS, Bottaro DP, Aaronson SA (1993) Hepatocyte growth factor/scatter factor and its receptor, the c-mel proto-oncogen e product. Biochem Biophys Acta 1155:357–371PubMedGoogle Scholar
  146. Sampson JR, Patel A, Mee AD (1995) Multifocal renal cell carcinoma in sibs from a chromosome 9 linked (TSC1) tuberous sclerosis family. J Med Genet 32:848–850PubMedCrossRefGoogle Scholar
  147. Santoro M, Carlomagno F, Romano A et al. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381–383PubMedCrossRefGoogle Scholar
  148. Schmidt D, Natt E, Neumann HPH (2000) Long-term results of laser treatment for retinal angiomatosis in von Hippel-Lindau disease. Eur J Med Res 5:47–58PubMedGoogle Scholar
  149. Schmidt L, Duh FM, Chen F et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73PubMedCrossRefGoogle Scholar
  150. Schmidt L, Junker K, Weirich G et al. (1998) Two North American families wilh hereditary papillary renal carcinoma and identical novel mutations in the MET protooncogene. Cancer Res 58:1719–1722PubMedGoogle Scholar
  151. Schmidt L, Junker K, Nakaigawa N et al. (1999) Novel mutations of the MET-protooncogene in papillary renal carcinoma. Oncogene 18:2343–2350PubMedCrossRefGoogle Scholar
  152. Schoenfeld A, Davidowitz EJ, Burk RD (1998) A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 95:8817–8822PubMedCrossRefGoogle Scholar
  153. Seipel K, Georgiev O, Schaffher W (1992) Different activation domains stimulate transcription from remote (“enhancer”). EMBO J 11:4961–4968PubMedGoogle Scholar
  154. Seizinger BR, Rouleau GA, Ozelius U et al. (1988) Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268–269PubMedCrossRefGoogle Scholar
  155. Sgambati MT, Stolle C, Choyke PL et al. (2000) Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offsprings with mosaic parents. Am J Hum Genet 66:84–91PubMedCrossRefGoogle Scholar
  156. Shipley JM, Birdsall S, Clark J et al. (1995) Mapping the X chromosome breakpoint in two papillary renal carcinoma cell lines with a t(X;1) (p11.2;q21.2) and the first report of a female case. Cytogenet Cell Genet 71:280–284PubMedCrossRefGoogle Scholar
  157. Shuin T, Kondo K, Torigoe S et al. (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852–2855PubMedGoogle Scholar
  158. Shuin T, Kondo K, Sakai N et al. (1996) A case of chromophobe renal cell carcinomas associated with low chromosome number and microsatellite instability. Cancer Genet Cytogenet 86:69–71PubMedCrossRefGoogle Scholar
  159. Sidhar SK, Clark J, Gill S et al. (1996) The t(X);1)-(p11.2;q21:2) translocation in papillary renal cell carcino-ma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet 5:1333–1338PubMedCrossRefGoogle Scholar
  160. Siemeister G, Weindel K, Möhrs K et al. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299–2301PubMedGoogle Scholar
  161. Skinnider BF, Jones EC (1999) Renal oncocytoma and chromophobe renal cell carcinoma. A comparison of colloidal iron staining and electron microscopy. Am J Clin Pathol 111:796–803PubMedGoogle Scholar
  162. Stebbins CE, Kaelin WG, Pavletich NP (1999) Structure of the VHL-elongin C-elongin B complex: implications for tumor suppressor function. Science 284:455–461PubMedCrossRefGoogle Scholar
  163. Stolle C, Glenn G, Zbar B et al. (1998) Improved detection of germline mutations in Von Hippel Lindau disease’s tumor suppressor gene. Hum Mutat 12:417–423PubMedCrossRefGoogle Scholar
  164. Storkel S, Berg A van den (1995) Morphological classification of renal cancer. World I Urol 13:153–158Google Scholar
  165. Szabo J, Heath B, Hill VM et al. (1995) Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome Iq21-q31. Am J Hum Genet 56:944–950PubMedGoogle Scholar
  166. Teh BT, Giraud S, Sari NF et al. (1997) Familial von-VHL, non-papil!ary clear cell RCC — a new entity. Lancet 349:848–849PubMedCrossRefGoogle Scholar
  167. Teh BT, Nord B, Kytola S et al. (1998a) Familial non-VHL, non-papillary renal cell carcinoma. 3rd International Symposium on von Hippel-Lindau disease, Paris, FranceGoogle Scholar
  168. Teh BT, Blennow E, Giraud et al. (1998b) Bilateral multiple renal oncocytomas and cysts associated with a constitutional translocation (8;9)(q24.1;q34.3) and a rare constitutional VHL missense substitution. Genes Chromosome Cancer 21:260–264CrossRefGoogle Scholar
  169. Teh BT, Farnebo F, Kristoffersson U et al. (2000) Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with adult nephroblastomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in nephroblastomas. J Clin Endocrinol Metab in pressGoogle Scholar
  170. Thoenes W, Storkel S, Rumpelt HJ (1986) Histopathology and classification of renal tumors (adenomas, oncocytomas, and carcinomas). The basic cytological and histopathological elements and their use in diagnostics. Pathol Res Pract 181:125–143PubMedCrossRefGoogle Scholar
  171. Thoenes W, Storkel St, Rumpelt HJ, Moll R (1990) Cytomorphological typing of renal cell carcinoma — a new approach. Eur Urol [Suppl 2] 18:6–9Google Scholar
  172. Tickoo SK, Amin MB (1998) Discriminant nuclear features of renal oncocytoma and chromophobe renal cell carcinoma. Analysis of their potential utility in the differential diagnosis. Am J Clin Pathol 110:782–787Google Scholar
  173. Toro J, Duray P, Glenn G et al. (1999) Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 135:1195–1202PubMedCrossRefGoogle Scholar
  174. Tory K, Brauch H, Linehan M et al. (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81:1097–1101PubMedCrossRefGoogle Scholar
  175. Trash-Bingham CA, Salazar H, Greenberg RA, Tartof KD (1996) Loss of heterozygosity studies indicate that chromosome 1p harbors a tumor suppressor gene for renal oncocytomas. Genes Chromosome Cancer 16:64–67CrossRefGoogle Scholar
  176. Tsujimura T (1996) Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells. Pathol Int 46:933–936PubMedCrossRefGoogle Scholar
  177. Tyers M, Rottapel R (1999) VHL: a very hip ligase. Proc Natl Acad Sci USA 96:12.230–12.232CrossRefGoogle Scholar
  178. Ubogy-Rainey Z, James WD, Lupton GP, Rodman OG (1987) Fibrofolliculomas, trichodiscomas, and acrochordons: the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 16:452–457PubMedCrossRefGoogle Scholar
  179. Van den Berg A, Dijkhuizen T, Störkel KS et al. (1995) Chromosomal changes in renal oncocytomas. Evidence that t(5;11) (q35;q13) may characterize a second subgroup of oncocytomas. Cancer Genet Cytogenet 79:165–168Google Scholar
  180. Van Slegtenhorst M, De Hoogt R, Hermans C et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277:803–808CrossRefGoogle Scholar
  181. Versteeg R (1997) Aberrant methylation in cancer. Am J Hum Genet 60:751–754PubMedGoogle Scholar
  182. Walther MM, Choyke PL, Glenn G et al. (1999) Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 161:1475–1479PubMedCrossRefGoogle Scholar
  183. Warfel KA, Eble JN (1982) Renal oncocytomatosis. J Urol 127:1179–1180PubMedGoogle Scholar
  184. Weirich G, Glenn G, Junker K et al. (1994) Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 160:335–340CrossRefGoogle Scholar
  185. Weterman MAJ, Wilbrink M, Dijkhuizen T, Van den Berg E, Van Kessel AG (1996a) Fine mapping of the 1q21 break-point of the papillary renal cell carcinoma-assodates (X;1) translocation. Hum Genet 98:16–21PubMedCrossRefGoogle Scholar
  186. Weterman MAJ, Wilbrink M, Geurts van Kessel A (1996b) Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1) (p11;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci USA 93:15.294–15.298CrossRefGoogle Scholar
  187. Whaley JM, Naglich J, Gelbert L et al. (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Am I Hum Genet 55:1092–1102Google Scholar
  188. Wiatrowska BA, Zakowski MF (1999) Fine-needle aspiration biopsy of chromophobe renal cell carcinoma and oncocytoma: comparison of cytomorphologic features. Cancer 87:161–167PubMedCrossRefGoogle Scholar
  189. Wienecke R, Maize JC, Shoarinejad F et al. (1996) Co-localization of the TSC2 product tuberin with its target Rapi in the Golgi apparatus. Oncogene 13:913–923PubMedGoogle Scholar
  190. Wienecke R, Maize JC, Reed JA, De Gunzburg J, Yeung RS, DeClue JE (1997) Expression of the TSC2 product tuberin and its target Rapi in normal human tissues. Am J Pathol 150:43–50PubMedGoogle Scholar
  191. Xiao GH, Shoarinejad F, Jin F et al. (1997) The tuberous sclerosis-2 gene product, tuberin functions as a Rab5GAP in modulating endocytosis. J Biol Chem 272:6097–6100PubMedCrossRefGoogle Scholar
  192. Yao M, Latif F, Orcutt ML et al. (1993) Von Hippel-Lindau disease: identification of deletion mutations by pulsed field gel electrophoresis. Hum Genet 92:605–614PubMedCrossRefGoogle Scholar
  193. Zbar B, Lerman M (1998) Inherited carcinomas of the kidney. Adv Cancer Res 75:163–201PubMedCrossRefGoogle Scholar
  194. Zbar B, Brauch H, Talmadge C, Linehan WM (1987) Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721–724PubMedCrossRefGoogle Scholar
  195. Zbar B, Tory K, Merino M et al. (1994) Hereditary papillary renal carcinoma. J Urol 151:561–566PubMedGoogle Scholar
  196. Zbar B, Glenn G, Lubensky I et al. (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153:907–912PubMedCrossRefGoogle Scholar
  197. Zbar B, Kishida T, Chen F et al. (1996) Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North American, Europe and Japan. Hum Mutat 8:348–357PubMedCrossRefGoogle Scholar
  198. Zhao WP, Gnarra JR, Liu S, Knutsen T, Linehan WM, Whang-Peng J (1995) Renal cell carcinoma. Cytogenetic analysis of tumors and cell lines. Cancer Genet Cytogenet 82:128–139PubMedCrossRefGoogle Scholar
  199. Zhuang Z, Park WS, Pack S et al. (1998) Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 20:66–69PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Hartmut P. H. Neumann
    • 1
  • Oliver Gimm
    • 2
  • Wilhelm Krek
    • 3
  • Bin Tean Teh
    • 4
  • Berton Zbar
    • 5
  1. 1.Albert-Ludwigs-Universität Medizinische UniversitätsklinikAbteilung Innere MedizinFreiburg im Breisgau
  2. 2.Klinik für AllgemeinchirurgieMartin-Luther-Universität Halle-WittenbergHalle
  3. 3.Friedrich-Miescher-InstitutBaselSchweiz
  4. 4.Van Andel Research InstituteGrand RapidsUSA
  5. 5.Laboratory of ImmunobiologyNCI-Frederick Cancer Research and Development CenterFrederickUSA

Personalised recommendations